ライフサイエンスコーパス: Klebsiella

1 arbapenemase bla-NDM-1 was being acquired by Klebsiella.

2 t of ceftriaxone non-susceptible E. coli and Klebsiella.

3 ) but lower reductions for E. coli (54%) and Klebsiella (42%).

4 eductions for the coliforms (E. coli 57% and Klebsiella 49%).

5 the ability of Enterococcus, Staphylococcus, Klebsiella, Acinetobacter, Pseudomonas, Enterobacter (ES

6 16 to 29% and 0% of mice with Salmonella and Klebsiella administrations, respectively.

7 s (n = 6), Citrobacter freundii (n = 4), and Klebsiella aerogenes (n = 2).

8 Enterobacter aerogenes was recently renamed Klebsiella aerogenes This study aimed to identify differ

9 to expansion of oral pathobionts, including Klebsiella and Enterobacter species, in the oral cavity.

10 resistant members of the genera Escherichia, Klebsiella and Enterobacter, genera commonly associated

11 sortium on Resistance Against Carbapenems in Klebsiella and Other Enterobacteriaceae, a prospective,

12 ated in 25 to 33% and 10 to 16% of mice with Klebsiella and Salmonella administrations, respectively.

13 tes included E. coli, Kluyvera, Providencia, Klebsiella, and Citrobacter species.

14 compared with those possessing Enterococcus, Klebsiella, and Enterobacter isolates from field-collect

15 ains of Gram-negative bacteria, Yersinia and Klebsiella, and less so by their wild-type counterparts.

16 units (PFUs) per milliliter for Pseudomonas, Klebsiella, and Serratia phages tested.

17 Klebsiella are significant human pathogens, frequently r

18 bers of this family, such as Escherichia and Klebsiella, are considered pathobionts and as such are c

19 Klebsiella bacteremia was demonstrated in 25 to 33% and

20 licon sequencing tool to screen patients for Klebsiella carriage could inform health care staff of th

21 ndividually at the genus level: Escherichia, Klebsiella, Enterobacter, Pseudomonas, and Stenotrophomo

22 from the genera Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella,

23 lostridiales), the second by Proteobacteria (Klebsiella/Enterobacter), the third by Bacteriodetes, an

24 LpxL2-dependent lipid A acylation protects Klebsiella from polymyxins, mediates resistance to phago

25 was accompanied by enhanced phagocytosis of Klebsiella GPVI-depleted mice showed increased lung hemo

26 The expression of Klebsiella hemolysin gene; TNF-alpha; IFN-beta; nucleoti

27 itro with various stimuli and in vivo during Klebsiella infection.

28 Two pan-resistant Klebsiella isolates were eradicated by combinations targ

29 Mannose-resistant Klebsiella-like (Mrk) hemagglutinins are critical for K

30 The ability to retain or share the commensal Klebsiella michiganensis, a member of the Enterobacteria

31 by Proteobacteria with Escherichia coli and Klebsiella most prevalent.

32 ent bacterial genera (Bacillus, Cupriavidus, Klebsiella, Ochrobactrum, Paenibacillus, Pseudomonas, an

33 l target detections exceeded 96%, except for Klebsiella oxytoca (92.2%), which achieved 98.3% sensiti

34 oli (n = 22), Enterobacter cloacae (n = 23), Klebsiella oxytoca (n = 8), Serratia marcescens (n = 6),

35 colitis (AAHC) caused by intestinal resident Klebsiella oxytoca Colitogenic strains produce the nonri

36 tube subunits, Hcp1, is required for killing Klebsiella oxytoca in vitro and that this activity is me

37 ne year after a GES-5 carbapenemase-positive Klebsiella oxytoca infection was identified by whole gen

38 nded-Spectrum (GES)-5 carbapenemase-positive Klebsiella oxytoca infection was identified by whole-gen

39 We subjected the corresponding positions of Klebsiella oxytoca NasR to site-directed alanine substit

40 of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus mirabilis with an ertape

41 , only three species, Klebsiella pneumoniae, Klebsiella oxytoca, and Providencia alcalifaciens, all m

42 D was originally discovered in the bacterium Klebsiella oxytoca, but it has recently been shown that

43 Enterobacter cloacae, Enterococcus faecalis, Klebsiella oxytoca, Klebsiella pneumoniae, and Staphyloc

44 an atomic model for a T2SS pseudopilus from Klebsiella oxytoca, obtained by fitting the NMR structur

45 ing Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mirabilis at >=50 000 col

46 In Klebsiella oxytoca, the pathway was enriched in clinical

47 Blood cultures were positive for Klebsiella oxytoca.

48 h CymA, a cyclodextrin-specific channel from Klebsiella oxytoca.

49 uster from either Rhodobacter sphaeroides or Klebsiella oxytoca.

50 xhibited good antibacterial activity against Klebsiella planticola with MIC of 15.6mug/mL and compoun

51 ells following immunization with heat-killed Klebsiella pneumonia (Kp).

52 1 is important for local host defense during Klebsiella pneumonia by maintaining adequate AM numbers

53 Here, we identify Klebsiella pneumonia in the microbiota of patients with

54 Klebsiella pneumonia infection rates have increased dram

55 is are powerful tools that can shed light on Klebsiella pneumonia infections.

56 The pathogenesis of Klebsiella pneumonia is linked to the bacteria's ability

57 res of Escherichia coli, Vibrio cholera, and Klebsiella pneumonia SlmA-DNA-FtsZ CTD ternary complexes

58 defenses during lethal pneumonia induced by Klebsiella pneumonia, compared to wild-type mice.

59 protected during lethal pneumonia induced by Klebsiella pneumonia, compared to wild-type mice.

60 Murine acute pneumonia model induced by Klebsiella pneumonia.

61 , Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumonia.

62 reptococcus agalactiae, Escherichia coli and Klebsiella pneumonia.

63 teria (Pseudomonas aeruginosa, 16-32 mug/mL, Klebsiella pneumoniae > 32 mug/mL).

64 jirovecii (18.8%), cytomegalovirus (15.6%), Klebsiella pneumoniae (15.6%), and Streptococcus pneumon

65 g-resistant Acinetobacter baumannii (52.2%), Klebsiella pneumoniae (22.4%), and Staphylococcus aureus

66 The most common baseline pathogens were Klebsiella pneumoniae (25.6%) and Pseudomonas aeruginosa

67 a pathogen (409/549 [74.5%]), predominantly Klebsiella pneumoniae (289/409 [70.1%]).

68 d intention-to-treat population (n=355) were Klebsiella pneumoniae (37%) and Pseudomonas aeruginosa (

69 The most frequent organism was Klebsiella pneumoniae (375 [86%] of 437; 291 [85%] of 34

70 the most common contributory pathogens were Klebsiella pneumoniae (86 [31%]), Streptococcus pneumoni

71 Infections caused by carpabenem-resistant Klebsiella pneumoniae (CR-Kp) are especially problematic

72 sortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) was constructed of patie

73 The rapid emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a major public h

74 k of OXA-232-expressing carbapenem-resistant Klebsiella pneumoniae (CRKP) transmitted to 16 patients

75 or infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKp).

76 Hypervirulent Klebsiella pneumoniae (hvKP) is an emerging pathotype th

77 Hypervirulent Klebsiella pneumoniae (hvKp) is globally disseminating a

78 -/-) mice were infected intratracheally with Klebsiella pneumoniae (KP) and assessed for extrapulmona

79 Carbapenem-resistance in Klebsiella pneumoniae (KP) sequence type ST258 is mediat

80 Two types of Klebsiella pneumoniae (KP) strains are currently emergin

81 57BL/6 mice inoculated with a lethal dose of Klebsiella pneumoniae (KP).

82 cells, during acute pneumonic infection with Klebsiella pneumoniae (KPn).

83 ne domain of the Outer membrane protein A of Klebsiella pneumoniae (KpOmpA).

84 ase genes were most frequently identified in Klebsiella pneumoniae (n = 1,127), Escherichia coli (n =

85 Klebsiella pneumoniae (n = 180, 41.9%), Escherichia coli

86 genes were detected by the Carba-R assay in Klebsiella pneumoniae (n = 236), Escherichia coli (n = 2

87 y resistant isolates of Escherichia coli and Klebsiella pneumoniae (PRIMERS I).

88 ogens Escherichia coli, Salmonella enterica, Klebsiella pneumoniae and Acinetobacter baumannii agains

89 e Neisseria gonorrhoeae datasets, as well as Klebsiella pneumoniae and Acinetobacter baumannii datase

90 y concentration values for Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.

91 linical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli.

92 bly identified pathogenic bacteria (that is, Klebsiella pneumoniae and Enterobacter cloacae) and thei

93 l rise in antimicrobial resistance (AMR) are Klebsiella pneumoniae and Enterobacter cloacae.

94 Klebsiella pneumoniae and Escherichia coli are part of t

95 ptococus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli in Conjunctiv

96 on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European h

97 Klebsiella pneumoniae and Escherichia coli were recovere

98 terferes with their cognate function against Klebsiella pneumoniae and Escherichia coli; vi) MAIT cel

99 s were detected from NP/OP specimens whereas Klebsiella pneumoniae and Mycobacterium tuberculosis wer

100 sortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) has

101 ainst Enterococcus faecium, platinum against Klebsiella pneumoniae and platinum and silver against Ac

102 y pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa.

103 d extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Salmonella typhimurium.

104 as Escherichia coli (ybaM), Dickeya solani, Klebsiella pneumoniae and Shigella flexneri.

105 DM)-producing strains of multidrug-resistant Klebsiella pneumoniae are a global public health threat

106 Escherichia coli and Klebsiella pneumoniae are opportunistic pathogens that a

107 , Micrococcus luteus, Bacillus subtilis, and Klebsiella pneumoniae at a minimal inhibitory concentrat

108 trains, notably against multi-drug resistant Klebsiella pneumoniae ATCC 700603 while isolates LB4 and

109 922, E. coli ATCC 35218, E. coli NCTC 13353, Klebsiella pneumoniae ATCC 700603, and Pseudomonas aerug

110 ein A (TTPA) is a structural tail protein of Klebsiella pneumoniae bacteriophage KP32, and is respons

111 CPOs carrying the Klebsiella pneumoniae carbapenemase (bla KPC ) gene have

112 CAZ-AVI displays in vitro activity against Klebsiella pneumoniae carbapenemase (KPC) enzyme produce

113 Klebsiella pneumoniae carbapenemase (KPC) is a widesprea

114 Imipenemase (IMP), Klebsiella pneumoniae carbapenemase (KPC), and Verona in

115 oncerning is the widespread dissemination of Klebsiella pneumoniae carbapenemase (KPC).

116 tam antibiotics due to the production of the Klebsiella pneumoniae carbapenemase (KPC-2) class A beta

117 nce to their genotypic profiles, whereas all Klebsiella pneumoniae carbapenemase (KPC; n = 8) and GES

118 n with an Enterobacter sp. isolate producing Klebsiella pneumoniae Carbapenemase-4 and New Delhi Meta

119 the most common transmissible CPE worldwide, Klebsiella pneumoniae carbapenemase-producing K. pneumon

120 the emergence and clinical impact of a novel Klebsiella pneumoniae carbapenemase-producing K. pneumon

121 e, in contrast to metallo-beta-lactamases or Klebsiella pneumoniae carbapenemases (KPC), no specific

122 em-resistant Enterobacteriaceae that produce Klebsiella pneumoniae carbapenemases.

123 Klebsiella pneumoniae carriage frequencies were estimate

124 We investigated the possible transmission of Klebsiella pneumoniae carrying mcr-1 via duodenoscope an

125 Klebsiella pneumoniae causes a wide range of infections,

126 Klebsiella pneumoniae causes pneumonia and liver abscess

127 Klebsiella pneumoniae causes severe lung and bloodstream

128 teriaceae, primarily involving KPC-producing Klebsiella pneumoniae clonal complex CC258.

129 fecal material, resulting in eradication of Klebsiella pneumoniae compared with nonresponders.

130 istent with regional clinical concern, e.g., Klebsiella pneumoniae contigs containing KPC-2 within an

131 of infections caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging.

132 nding global distribution of multi-resistant Klebsiella pneumoniae demands faster antimicrobial susce

133 Here we show that mice infected with Klebsiella pneumoniae develop lung injury with accumulat

134 te the antagonism between the microbiota and Klebsiella pneumoniae during colonization and transmissi

135 seudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae from resin-containing BacT/Alert F

136 Klebsiella pneumoniae harboring blaKPC (KPC-Kpn) is ende

137 nst clinical isolates of Eschericia coli and Klebsiella pneumoniae harboring NDM-1 were reduced to su

138 Klebsiella pneumoniae has a reputation for causing a wid

139 Carbapenemase-producing Klebsiella pneumoniae has become a global priority, not

140 idrug resistant (MDR) opportunistic pathogen Klebsiella pneumoniae has previously been shown to adapt

141 lly track a clonal outbreak of blaKPC-pKpQIL-Klebsiella pneumoniae in a proof-of-principle study.

142 ogues with in vivo efficacy against MRSA and Klebsiella pneumoniae in animal models of infection.

143 a17 cell numbers in vivo, we used a model of Klebsiella pneumoniae in mice deficient in STAT6.

144 so show that expression of Gam in E. coli or Klebsiella pneumoniae increases sensitivity to fluoroqui

145 Carbapenem-resistant Klebsiella pneumoniae infections are increasingly preval

146 Klebsiella pneumoniae is a common cause of antibiotic-re

147 Klebsiella pneumoniae is a common cause of antimicrobial

148 Klebsiella pneumoniae is a Gram-negative bacterial patho

149 Klebsiella pneumoniae is a human pathogen, prominent in

150 Klebsiella pneumoniae is a human, animal, and environmen

151 Klebsiella pneumoniae is a major threat to public health

152 Klebsiella pneumoniae is a respiratory, blood, liver, an

153 Klebsiella pneumoniae is an important human pathogen cau

154 Klebsiella pneumoniae is an important pathogen in the co

155 Multidrug-resistant Klebsiella pneumoniae is an increasing cause of infant m

156 Klebsiella pneumoniae is an opportunistic pathogen and l

157 omial infections due to carbapenem-resistant Klebsiella pneumoniae is increasing worldwide.

158 Klebsiella pneumoniae is part of the healthy human micro

159 esequencing of three plasmids in a reference Klebsiella pneumoniae isolate demonstrated approximately

160 g-resistant, carbapenemase (KPC-3)-producing Klebsiella pneumoniae isolate.

161 Klebsiella pneumoniae isolated from screening swabs and

162 ion of long- and short-read sequence data of Klebsiella pneumoniae isolates (n = 1,717) from a Europe

163 ically-related NDM-1 carbapenemase producing Klebsiella pneumoniae isolates identified during an outb

164 were found among the Enterobacterales (for 2 Klebsiella pneumoniae isolates).

165 prim-resistant clinical Escherichia coli and Klebsiella pneumoniae isolates, suggesting that they may

166 Escherichia coli PI-7, blaCTX-M-15-positive Klebsiella pneumoniae L7, and blaOXA-48-positive E. coli

167 Here, we show the increased prevalence of Klebsiella pneumoniae lipopolysaccharide O2 serotype str

168 d in O-antigenic polysaccharides (OPSs) from Klebsiella pneumoniae lipopolysaccharides.

169 Klebsiella pneumoniae liver abscess (KLA) is emerging wo

170 Here we report the crystal structure of Klebsiella pneumoniae LpxH in complex with AZ1.

171 mmunities consisting of Escherichia coli and Klebsiella pneumoniae once antibiotics were removed.

172 ns and no ongoing outbreak of ESBL-producing Klebsiella pneumoniae or Enterobacter spp.

173 dministration of pathogenic bacteria, either Klebsiella pneumoniae or Salmonella enterica serovar Typ

174 (FMDV) veterinary outbreak in England and a Klebsiella pneumoniae outbreak in a Nepali neonatal unit

175 Klebsiella pneumoniae poses a major challenge to healthc

176 the current epidemic of carbapenem-resistant Klebsiella pneumoniae rely on a comprehensive understand

177 Klebsiella pneumoniae remains an important cause of intr

178 The extracellular polysaccharide capsule of Klebsiella pneumoniae resists penetration by antimicrobi

179 Carbapenem-resistant Klebsiella pneumoniae sequence type 258 (CRKP-ST258) can

180 t the capsular polysaccharide of a dominated Klebsiella pneumoniae serotype K2 is difficult to synthe

181 The Klebsiella pneumoniae species complex includes important

182 Europe, carbapenem-resistant strains of the Klebsiella pneumoniae ST258 (ref.

183 ATCC 25922, CM-13457, and CM-10455) and one Klebsiella pneumoniae strain (CM-11073) were grown overn

184 We previously isolated a Klebsiella pneumoniae strain, NTUH-K2044, from a communi

185 Carbapenem-resistant Klebsiella pneumoniae strains classified as multilocus s

186 ence of mcr-1 was investigated in E coli and Klebsiella pneumoniae strains collected from five provin

187 ing the sequence type 258 (ST258) lineage of Klebsiella pneumoniae There was very little evidence of

188 to killing by serum enhances the capacity of Klebsiella pneumoniae to cause infection, but it is an i

189 1 hypomorphic (Hypo) mice were infected with Klebsiella pneumoniae to determine infectious burden, im

190 survey of clinical polymyxin-resistant (PR) Klebsiella pneumoniae to determine the molecular mechani

191 acheally inoculated with either live or dead Klebsiella pneumoniae to induce either lung infection or

192 , as well as in a model of lung infection by Klebsiella pneumoniae Transferring serum from Ig-deficie

193 by encapsulated pathogens, there is still no Klebsiella pneumoniae vaccine available.

194 ) mice with the common human sepsis pathogen Klebsiella pneumoniae via the airways to induce pneumoni

195 teria could reduce bacterial burden in vivo, Klebsiella pneumoniae was injected into the tail veins o

196 Klebsiella pneumoniae was isolated from cattle, poultry,

197 Klebsiella pneumoniae was isolated from stool of 17/149

198 T CRE infection was identified in 59 (15.7%) Klebsiella pneumoniae was isolated in 83.2%; surgical si

199 sphoenolpyruvate carboxylase gene (ppc) from Klebsiella pneumoniae was overexpressed to access the on

200 netobacter baumannii and multidrug-resistant Klebsiella pneumoniae was treated with bacteriophages an

201 Enterococcus spp., Escherichia coli and Klebsiella pneumoniae were the common bacterial pathogen

202 studied the recovery of Escherichia coli and Klebsiella pneumoniae when exposed to meropenem, imipene

203 ndogenous endophthalmitis is associated with Klebsiella pneumoniae whereas Coagulase negative Staphyl

204 During 2013, ST278 Klebsiella pneumoniae with blaNDM-7 was isolated from th

205 Escherichia coli, Pseudomonas aeruginosa, or Klebsiella pneumoniae) isolated from clinical cases.

206 m negative bacteria (e.g., Escherichia coli, Klebsiella pneumoniae) with varying levels of antibiotic

207 Klebsiella pneumoniae, a bacterial pathogen that has acq

208 Klebsiella pneumoniae, a chief cause of nosocomial pneum

209 Klebsiella pneumoniae, a Gram-negative bacterium, is not

210 I agents, and multidrug-resistant strains of Klebsiella pneumoniae, a leading HAI agent, have caused

211 as historically largely been associated with Klebsiella pneumoniae, a predominant plasmid (pKpQIL), a

212 rum activity, encompassing Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomon

213 p., Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomo

214 Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomo

215 Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomo

216 Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomo

217 ith wound infections: Staphylococcus aureus, Klebsiella pneumoniae, and Acinetobacter baumannii.

218 n Escherichia coli, Pseudomonas syringae and Klebsiella pneumoniae, and endogenous CRISPR-Cas use was

219 omycin-resistant Enterococcus faecium (VRE), Klebsiella pneumoniae, and Escherichia coli in the intes

220 riggered by LPS from Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli Sixteen cyto

221 bacterium tuberculosis, Salmonella enterica, Klebsiella pneumoniae, and Escherichia coli We compare p

222 nt strains, such as Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli.

223 of Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, and Pseudomonas aeruginosa We the

224 Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were t

225 cies-Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa-report

226 , Enterococcus faecalis, Klebsiella oxytoca, Klebsiella pneumoniae, and Staphylococcus aureus at age

227 ucosal challenge with the pulmonary pathogen Klebsiella pneumoniae, and substantially reduced epithel

228 resistant (MDR) carbapenemase-producing (CP) Klebsiella pneumoniae, belonging to clonal group CG258,

229 ridium perfringens, Ruminococcus gnavus, and Klebsiella pneumoniae, but also beneficial species, such

230 portant carbapenem-resistant human pathogen, Klebsiella pneumoniae, by B. bacteriovorus in human seru

231 cy, lung disease, baseline urine source, and Klebsiella pneumoniae, compared to the Escherichia coli

232 am-negative bacteria on clinical isolates of Klebsiella pneumoniae, containing highly-resistant antim

233 nterococcus faecium and carbapenem-resistant Klebsiella pneumoniae, emerge from the intestinal lumen

234 Klebsiella pneumoniae, Escherichia coli, and other membe

235 ta that produces SCFAs enhances clearance of Klebsiella pneumoniae, Escherichia coli, and Proteus mir

236 of antibiotic-resistant clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Proteus mir

237 a, Proteus mirabilis, Enterococcus faecalis, Klebsiella pneumoniae, Escherichia coli, and Staphylococ

238 the major uropathogens Proteus mirabilis and Klebsiella pneumoniae, in addition to UPEC, in humans.

239 lipopolysaccharide transporter LptB2FG from Klebsiella pneumoniae, in which both LptF and LptG are c

240 d in vivo during pneumoseptic infection with Klebsiella pneumoniae, indicating its regulatory role in

241 (1) urine cultures growing Escherichia coli, Klebsiella pneumoniae, K. oxytoca, or Proteus mirabilis

242 428) and 9,371 isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus m

243 after this death phase, only three species, Klebsiella pneumoniae, Klebsiella oxytoca, and Providenc

244 (1) urine cultures growing Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mi

245 ei, Chlamydia trachomatis, Escherichia coli, Klebsiella pneumoniae, Legionella pneumophila, Pseudomon

246 For Klebsiella pneumoniae, Mycobacterium tuberculosis, Salmo

247 1%) of 5332 E coli isolates, 13 (<1%) of 348 Klebsiella pneumoniae, one (<1%) of 890 Enterobacter clo

248 l isolates of either Pseudomonas aeruginosa, Klebsiella pneumoniae, or Staphylococcus aureus produces

249 PS) of the multiresistant clinical strain of Klebsiella pneumoniae, PCM2713, and thus should be regar

250 he Gram-negative pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acine

251 Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Esche

252 f Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphyloc

253 A phenotype of Escherichia coli and Klebsiella pneumoniae, resistant to piperacillin/tazobac

254 raperitoneally (i.p.) with Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, lipopol

255 wk and then challenged intratracheally with Klebsiella pneumoniae, Streptococcus pneumoniae, or lipo

256 o human pathogens, Staphylococcus aureus and Klebsiella pneumoniae, that utilize this metal nutrient

257 umonic sepsis using pulmonary infection with Klebsiella pneumoniae, the expression of MGL1 was upregu

258 cation of DNA from Staphylococcus aureus and Klebsiella pneumoniae, two pathogens commonly related to

259 coccus faecalis, Pseudomonas aeruginosa, and Klebsiella pneumoniae, which are frequently implicated i

260 electin participates in host defense against Klebsiella pneumoniae-induced pulmonary inflammation is

261 (MDR) strains of Salmonella Typhimurium and Klebsiella pneumoniae.

262 cture of an assembled T2SS from the pathogen Klebsiella pneumoniae.

263 carbapenemase OXA-48, in lysate samples from Klebsiella pneumoniae.

264 human pathogens Streptococcus pneumoniae and Klebsiella pneumoniae.

265 ococcus faecium, Acinetobacter baumannii and Klebsiella pneumoniae.

266 verlapping AR genes, and are correlated with Klebsiella pneumoniae.

267 Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae.

268 orbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

269 t within 4 h for Acinetobacter baumannii and Klebsiella pneumoniae.

270 for the vaccine against the K2 sero group of Klebsiella pneumoniae.

271 activity against Acinetobacter baumannii and Klebsiella pneumoniae; however, analogue 9 and 16 at 4 m

272 ly studied in some enteric bacteria, such as Klebsiella pneumoniae; however, their role in pathogenes

273 er UTI and non-UTI bacteria, Staphylococcus, Klebsiella, Proteus and Shigella.

274 ntial importance in Escherichia, Salmonella, Klebsiella, Shigella, and Yersinia opportunistic pathoge

275 whereas mold decreased by 1 LU, E. coli and Klebsiella sp. by 2 LU, Salmonella sp. and Shigella sp.

276 se negative staphylococci (CoNS) (33.5%) and Klebsiella species (4.7%).

277 resistance rates for some organisms, such as Klebsiella species and Pseudomonas aeruginosa, were lowe

278 nt (including Enterococcus, Enterobacter and Klebsiella species), in babies delivered by caesarean se

279 ns, including Photorhabdus, Xenorhabdus, and Klebsiella species, amongst others.

280 o had HO bacteremia due to Escherichia coli, Klebsiella species, or Pseudomonas aeruginosa at 130 VHA

281 in Escherichia coli, from 11.8% to 90.5% in Klebsiella spp and from 30.4% to 71.9% in other Enteroba

282 5% to 31.1% in E coli, from 1.7% to 70.2% in Klebsiella spp and from 5.9% to 68.8% in other Enterobac

283 acteraemia or sepsis, Staphylococcus aureus, Klebsiella spp, and Escherichia coli accounted for 25% (

284 ine pathogens: Pseudomonas aeruginosa (77%), Klebsiella spp. (16%), other Enterobacteriaceae (6%).

285 ytogenes, Haemophilus influenzae, S. aureus, Klebsiella spp. and non-typhoidal Salmonella bacteria.

286 rium spp., and reduction of Enterococcus and Klebsiella spp. in vaginally delivered infants.

287 tobiotic techniques, we show that strains of Klebsiella spp. isolated from the salivary microbiota ar

288 For example, cephalosporin-resistant Klebsiella spp. provoked carbapenem use less than E. col

289 Among children <=5 years, Klebsiella spp. resistance to all first-line antimicrobi

290 all Escherichia coli, Enterobacter spp., or Klebsiella spp. resistant to >=1 carbapenem were reporte

291 coliform (Escherichia coli, Proteus spp., or Klebsiella spp.) bacteraemia among adult (18+ years) pat

292 etrospective review of all Escherichia coli, Klebsiella spp., and Enterobacter spp. tested by MicroSc

293 a-lactam susceptibility in Escherichia coli, Klebsiella spp., and Proteus mirabilis was evaluated, us

294 of gram-negative bacteria (Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, and Acinetobact

295 These Klebsiella strains are resistant to multiple antibiotics

296 Science, Atarashi et al. (2017) showed that Klebsiella strains isolated from the saliva of Crohn's d

297 d with PpdD pili assembled in a heterologous Klebsiella T2SS type 2 secretion system (T2SS) by using

298 ntaining enzymes, Salmonella hydrogenase and Klebsiella urease.

299 clonal outbreak of multidrug-resistant (MDR) Klebsiella variicola (sequence type [ST] 771) in a Bangl

300 tly, ectopic colonization of the gut by oral Klebsiella was documented to induce dysbiosis and inflam